Results 1 to 10 of about 171,246 (253)
Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells
Cancer Cell International, 2018 Background Multidrug resistance (MDR) is a major obstacle in breast cancer treatment. The predominant mechanism underlying MDR is an increase in the activity of adenosine triphosphate (ATP)-dependent drug efflux transporters.
Shao-hsuan Wen +4 more
doaj +1 more source
Molecular Medicine, 2021 Background Previous studies showed that doxorubicin could lead to osteoarthritis (OA) by inducing chondrocyte inflammation and apoptosis. Besides, it is reported that platelet-rich plasma (PRP) could suppress the activation of inflammatory NF-κB ...
Haijun Zhao +3 more
doaj +1 more source
BMC Veterinary Research, 2021 Background Both human and veterinary cancer chemotherapy are undergoing a paradigm shift from a “one size fits all” approach to more personalized, patient-oriented treatment strategies.
Kristine Walters +9 more
doaj +1 more source
Exposure to Doxorubicin Modulates the Cardiac Response to Isoproterenol in Male and Female Mice
Pharmaceuticals, 2023 Sex is a salient risk factor in the development of doxorubicin-induced cardiotoxicity. Sex differences in the heart’s ability to respond to hypertrophic stimuli in doxorubicin-exposed animals have not been reported.
Kevin Agostinucci +4 more
doaj +1 more source
TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC
Tumor Biology, 2017 The anticancer effect of doxorubicin is closely related to the generation of reactive oxygen species. On the contrary, doxorubicin-induced reactive oxygen species induces heart failure, a critical side effect of doxorubicin.
Yun Sun Lee +5 more
doaj +1 more source
BMC Cancer, 2012 Background Since proteins involved in chemotherapy drug pharmacokinetics and pharmacodynamics have a strong impact on the uptake, metabolism, and efflux of such drugs, they likely play critical roles in resistance to chemotherapy drugs in cancer patients.
Heibein Allan D +4 more
doaj +1 more source
Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency.
PLoS ONE, 2019 Doxorubicin is a chemotherapeutic agent that is commonly used to treat a broad range of cancers. However, significant cardiotoxicity, associated with prolonged exposure to doxorubicin, limits its continued therapeutic use.
Christina Schindler +7 more
doaj +1 more source
Cancer Innovation, 2023 Background Doxorubicin is a widely used cytotoxic chemotherapy agent for treating different malignancies. However, its use is associated with dose‐dependent cardiotoxicity, causing irreversible myocardial damage and significantly reducing the patient's ...
Qingling Zhang +9 more
doaj +1 more source
Pharmaceutics, 2023 Doxorubicin is a potent chemotherapeutic drug; however, its clinical application has been limited due to its cardiotoxicity. One of the major mechanisms of doxorubicin-induced cardiotoxicity is the induction of oxidative stress.
Tanawat Attachaipanich +2 more
doaj +1 more source
Electrochemical Behaviour of Doxorubicin Encapsulated in Apoferritin
International Journal of Electrochemical Science, 2013 A voltammetric detection of doxorubicin and encapsulated doxorubicin in apoferritin structure at a carbon paste electrode is the main aim of this study. The samples were measured by differential pulse voltammetry in phosphate buffer (pH 5.5).
Katerina Tmejova +11 more
doaj +1 more source